The Kebeza ecosystem

Care is a chain.
Build every link.

Awareness brings someone to care. A prepared specimen reaches a specialist. A patient knows what to do next. Evidence can improve the next journey, with the right permissions.

Explore the system

Service architecture

Follow the work.
See what is ready.

Select a layer for its role, current status and related projects. See how these parts could support the future Cancer Intelligence System.

Clinical service experience

Real specimens. Prepared well.

Collection, preparation and staining make remote review possible. Regional experience with affiliated clinics spans Mbale Pathology Clinic, JPC Pathology Clinic in Jinja and Oak Pathology Clinic in Arua, alongside trained operators and cytotechnologists.

Platform in development

The right expertise, around each case.

PathEdge is being developed to coordinate acquisition, remote review, second opinions and quality assurance across cytology and histology. Pathologists interpret and sign final reports.

In use within Mulago pathology

A result needs a next step.

Rosemary operates within pathology services at Mulago National Referral Hospital, Uganda. It helps patients check result readiness, request FNAC appointments and navigate services. Further referral and follow-up coordination is planned.

Research direction

Towards one
Cancer Intelligence System.

Connect the work of diagnosis with the evidence needed for the next decision. The proposed architecture builds on physical services, PathEdge’s development and Rosemary’s patient-access role.

CARE → EVIDENCE → SUPPORT → EVALUATIONProposed integration
01

Service foundation

Clinical experience

Physical diagnostics

Local collection, preparation and staining. Cytology and histology need suitable specimens and trained teams.

Clinical services
In development

PathEdge

Acquisition, specialist review, quality assurance and reporting. Qualified pathologists retain final sign-out.

Specialist workflow
In use at Mulago pathology

Rosemary

Result-status checks, appointment requests and service navigation. A patient-access layer for the next step.

Patient access

Permission before connection

Consent or another legal basis, ethics review, institutional permissions and agreements define approved use. Access controls and de-identification apply. No automatic record linking, transfer to external models or external-model training.

02
PROPOSED EVIDENCE LAYER

Only what is authorised.

  • Pathology images & reportsPermissioned records with source and review history
  • Pathway eventsPreparation, review, result readiness and referral steps
  • Research datasetsStudy-approved registries and evaluated evidence
  • Clinical & molecular contextFuture inputs, where separately authorised
03
HUMAN-SUPERVISED SUPPORT

Prepare. Retrieve. Review.

In development

Support the diagnostic workflow

Report preparation, acquisition and documentation checks, and multilingual navigation.

Proposed

Support the oncology team

Retrieve relevant evidence and organise approved pathology, clinical and molecular context for tumour-board and precision-oncology review.

Agentic support would coordinate these tasks, show its sources and flag missing information for a clinician to review.

This integrated system is proposed, not a live unified backend. It would support clinical teams without autonomous diagnosis. Qualified pathologists retain diagnosis and final sign-out.

From a prepared case
to an informed discussion.

The aim is to make relevant information easier for clinical teams to use: a better-prepared report, a missing detail brought to attention, or evidence ready for a tumour-board discussion. The African Precision Oncology Atlas is one proposed programme within this broader direction.

Explore the precision-oncology direction
Follow a proposed case pathway
  1. A local team prepares the specimen; a qualified pathologist reviews and signs the report through an evaluated workflow.
  2. Only records authorised for the specific purpose could cross into the evidence layer. Rosemary’s access role does not automatically link a patient’s records.
  3. Supervised tools could assemble permitted case context and relevant sources for the oncology team, showing gaps for human review.
  4. The team makes the clinical decision. Separately approved evaluation could identify improvements to acquisition, review or navigation and return them to care.

Public-hospital records remain institution-governed. Patient data are not offered for sale.

Discuss an evaluation or research package

What is happening, and what comes next

What is operating.
What comes next.

Clinical work informs the next stage: evaluated acquisition, specialist coordination and governed evidence.

Current operations

Care, navigation and education

Regional cytology experience, Rosemary within Mulago pathology services, and public education in Luganda and English.

In development

PathEdge and acquisition workflows

Scanner-agnostic coordination, reporting and quality review. PathEdge is founder-funded and pre-revenue. Multilingual access improvements are in development.

Proposed research

Independent evaluation

Retrospective and prospective image/glass review, cervical screening and triage studies, governed registries and pathway feasibility. Subject to institutional and ethics approvals.

Long-term direction

Human-supervised cancer intelligence

APOA and future precision-oncology support would connect permissioned clinical, pathology and molecular evidence for oncology teams.

Kebeza Project · Education in development

Generative video, Blender-based scientific visualisation and interactive 3D medical education are development ambitions for explaining cancer and diagnostic pathways.

Explore the education work

Research that answers practical questions

Does the pathway work?
For whom, and at what cost?

Proposed retrospective work would retrieve historical remote-cytology records, images and glass slides where available. Blinded rereads, a second independent pathologist and histology correlation where available would test the evidence.

Parallel proposals include HPV self-collection validation, p16/Ki-67 triage and same-day cytology feasibility. Histology acquisition and reporting remain part of Kebeza’s wider programme.

Mulago National Referral Hospital, Uganda, is the proposed institutional research lead, with Dr Sharrif Musoke as proposed principal investigator. Subject to approvals, institutional agreements and funding. Kebeza’s proposed contribution is technical and service implementation.

Explore research work packages

Find your place in the work

Better capacity starts
with a concrete next step.